Koji Tomita

Koji Tomita

Auto-generated profile, based on publicly available information

Koji Tomita

Department of Radiology, Okayama University Hospital, Okayama, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Japanese Journal of Radiology
Verified
Journal Article
Open access
PDF file
KTKoji Tomita
Koji Tomita
YMYusuke Matsui
Yusuke Matsui
MUMayu Uka
Mayu Uka
NUNoriyuki Umakoshi
Noriyuki Umakoshi
TKTakahiro Kawabata
Takahiro Kawabata
THTakao Hiraki
Takao Hiraki
Purpose: This review aimed to summarize the treatment outcomes of percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA) for metastatic liver tumors based on the findings of published studies over the last decade. Materials and methods: Literature describing the survival outcomes of ablation therapy for liver metastases was explored using the PubMed database on April 26, 2022, and articles published in 2012 or later were selected. The included studies met the following criteria: (i) English literature, (ii) original clinical studies, and (iii) literature describing overall survival (OS) of thermal ablation for metastatic liver tumors. All case reports and cohort studies with fewer than 20 patients and those that evaluated ablation for palliative purposes were excluded. Results: RFA was the most commonly used method for ablation, while MWA was used in several recent studies. RFA and MWA for liver metastases from various primary tumors have been reported; however, majority of the studies focused on colorectal cancer. The local control rate by RFA and MWA varied widely among the studies, ranging approximately 50–90%. Five-year survival rates of 20–60% have been reported following ablation for colorectal liver metastases by a number of studies, and several reports of 10-year survival rates were also noted. Conclusion: Comparative studies of local therapies for colorectal liver metastases demonstrated that RFA provides comparable survival outcomes to surgical metastasectomy and stereotactic body radiation therapy.

28 May 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
KTKoji Tomita
Koji Tomita
TIToshihiro Iguchi
Toshihiro Iguchi
YMYusuke Matsui
Yusuke Matsui
MUMayu Uka
Mayu Uka
NUNoriyuki Umakoshi
Noriyuki Umakoshi
THTakao Hiraki
Takao Hiraki

1 April 2023 in Japanese Journal of Radiology
Verified
Journal Article
Open access
PDF file
NUNoriyuki Umakoshi
Noriyuki Umakoshi
TIToshihiro Iguchi
Toshihiro Iguchi
YMYusuke Matsui
Yusuke Matsui
KTKoji Tomita
Koji Tomita
MUMayu Uka
Mayu Uka
THTakao Hiraki
Takao Hiraki
Purpose: To retrospectively evaluate cryoablation combined with prior transcatheter arterial embolization (TAE) for renal cell carcinoma (RCC) in non-dialysis patients with stage 4 or 5 chronic kidney disease (CKD). Materials and methods: Patients with stage 4 or 5 CKD undergoing TAE and cryoablation for RCC between May 2012 and October 2021 were included. TAE was selectively performed using iodized oil with absolute ethanol or gelatin sponge 1–14 days before cryoablation. Local efficacy, safety, and changes in renal function were evaluated. Results: Nine patients (seven men and two women; median age, 64 years; range 52–88 years) with nine RCCs (mean diameter, 3.0 ± 1.0 cm; range 1.7–4.7 cm) were included. The mean pre-treatment estimated glomerular filtration rate (eGFR) was 24.2 ± 5.6 ml/min/1.73 m2 (range 10.4–29.2 ml/min/1.73 m2). The mean amount of contrast medium used in TAE was 58 ± 29 ml (range 40–128 ml). Except in one patient (grade 3 pyelonephritis), no grade ≥ 3 complications occurred. During the follow-up period (median, 18 months; range 7–54 months), no local tumor progression occurred. In two patients with pre-treatment eGFR of < 20 ml/min/1.73 m2, hemodialysis was initiated at 3 and 19 months after cryoablation. At their last follow-up, the remaining seven patients showed a decrease of 6.2 ± 5.3 ml/min/1.73 m2 (range 0.7–17.2 ml/min/1.73 m2) in their eGFR. Conclusion: Cryoablation combined with TAE for RCC in non-dialysis patients with stage 4 or 5 CKD was effective and safe, with an acceptable impact on renal function.

1 January 2015 in Internal Medicine
Verified
Journal Article
Open access
TTTakashi Tanaka
Takashi Tanaka
HGHideo Gobara
Hideo Gobara
KTKoji Tomita
Koji Tomita
THTakao Hiraki
Takao Hiraki
TTTakehiro Tanaka
Takehiro Tanaka
SKSusumu Kanazawa
Susumu Kanazawa
Hepatic intracystic hemorrhage is a rare complication of polycystic liver diseases, such as autosomal dominant polycystic kidney disease (ADPKD). A hepatic cyst with mural nodules and septation may suggest the presence of a cystic malignancy, such as biliary cystadenocarcinoma. We herein report a case of hepatic intracystic hematoma with a mural nodule mimicking biliary cystadenocarcinoma in a patient with ADPKD. Hepatic intracystic hemorrhage with a mural nodule is a very rare occurrence. A fat-saturated T1-weighted magnetic resonance image may be useful for making an accurate diagnosis of intracystic hematoma.

8 February 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
TIToshihiro Iguchi
Toshihiro Iguchi
YMYusuke Matsui
Yusuke Matsui
KTKoji Tomita
Koji Tomita
MUMayu Uka
Mayu Uka
NUNoriyuki Umakoshi
Noriyuki Umakoshi
THTakao Hiraki
Takao Hiraki

21 June 2022 in Japanese Journal of Radiology
Verified
Journal Article
Open access
PDF file
MUMayu Uka
Mayu Uka
TIToshihiro Iguchi
Toshihiro Iguchi
NONanako Okawa
Nanako Okawa
YMYusuke Matsui
Yusuke Matsui
KTKoji Tomita
Koji Tomita
THTakao Hiraki
Takao Hiraki
Purpose: To retrospectively assess the feasibility, safety, renal function, technique efficacy rate, and survival of patients with clinical T3a renal cell carcinoma (RCC). Materials and methods: Sixteen cryoablation sessions were performed in 14 patients (10 men; mean age, 69.8 ± 10.5 years; range, 49–90 years) with 14 clear cell T3a RCCs (mean, 3.3 ± 0.9 cm; range, 1.9–5.2 cm). One patient was on dialysis. Transcatheter arterial embolization was performed before cryoablation in 15 sessions. The primary endpoint was the technique efficacy rate. The secondary endpoints included feasibility, safety, renal function, and survival. Results: Cryoablation was technically successful in all RCC cases. In two RCCs, cryoablation was performed twice because of local tumor progression. No major adverse events were observed. All patients were alive without metastases, with a median follow-up of 45 months (6−93 months). Complete response was achieved by cryoablation in 11 RCCs (78.6%). The primary and secondary technique efficacy rates were 77.1% and 84.4% at 1 year, 57.9% and 73.9% at 3 years, and 57.9% and 73.9% at 5 years, respectively. One patient underwent dialysis given a total contralateral nephrectomy due to another RCC 1 month after initial cryoablation and a total ipsilateral nephrectomy 46 months after initial cryoablation due to local progression. Except for two dialysis patients, of the 12 patients with a median follow-up of 41 months (6–93 months), none were on dialysis. Conclusion: Cryoablation was safe and effective in T3a RCC, which mainly involved the renal venous branches and may represent an alternative treatment for inoperable patients.